Neovacs S.A. is a French biotechnology company specializing in the development of therapeutic vaccines, primarily targeting autoimmune, inflammatory, allergy, and cancer diseases. The company’s core innovation lies in its proprietary "Kinoid" technology platform, which enables active immunotherapy by regulating the overproduction of cytokines involved in disease processes. Notable products in its pipeline include the IFNa Kinoid vaccine, for which clinical trials are underway for lupus erythematosus and dermatomyositis, and an IL-4/IL-13 Kinoid vaccine in preclinical stages for allergy treatment. Beyond R&D, Neovacs also leverages its expertise through investments in other innovative biotech and medtech firms. Founded in 1993 and headquartered in Paris, Neovacs plays a significant role in advancing therapeutic vaccine technology within the healthcare and biotechnology sectors.